Systemic Mastocytosis
Systemic mastocytosis is a rare condition where there is an excessive number of mast cells in the body, which can lead to various symptoms affecting the skin, gastrointestinal tract, and other organs.
Avapritinib: Continued Access for Previous Study Participants
We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you currently receiving or have you recently taken avapritinib?
- Are you pregnant or breastfeeding?
- Have you completed the end of treatment visit in your previous study?
- Are you participating in another interventional study?
- Are you able to comply with study procedures and restrictions?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Antwerp University Hospital
Immunology - Allergology - Rheumatology
Wilrijk, Belgium
Azienda Ospedaliera Universitaria San Giovanni Di Dio E Ruggi d'Aragona
Department of Medicine, Division of Allergy and Immunology, University of Salerno
Salerno, Italy
Universitair Medisch Centrum Groningen
Department of Internal Medicine
Groningen, Netherlands
Sponsor: Blueprint Medicines Corp.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.